This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
14 Jun 2016

Rx-360 summary of the draft WHO HVAC GMPs for non-sterile products

Document is intended to provide guidance to pharmaceutical manufacturers and inspectors of pharmaceutical manufacturing facilities on the design, installation, qualification and maintenance of the HVAC systems.

WHO has issued a revision to their supplementary guidelines on GMP for HVAC systems for non-sterile pharmaceutical dosage forms. This draft was generated based on the feedback received from inspectors, the new, current trends in engineering and the experience gained during the implementation of this guidance in inspections. This update also includes improved graphic images to make them more readable.

These guidelines primarily focus on the design and GMP requirements and recommendations for HVAC systems for facilities for the manufacture of non-sterile solid dosage forms. This includes tablets, capsules, powders, liquids, creams and ointments. The HVAC design principles contained in the guidelines may be applied to other dosage forms.

This document is intended to provide guidance to pharmaceutical manufacturers and inspectors of pharmaceutical manufacturing facilities on the design, installation, qualification and maintenance of the HVAC systems. These guidelines are intended to complement those provided in GMPs for pharmaceutical products and should be read in conjunction with the parent guide. The additional standards addressed by the present guidelines should, therefore, be considered supplementary to the general requirements set out in the main principles guide (WHO Technical Report Series, No. 961, Annex 3).

Along with a glossary of terms, this guidance document discusses commissioning, qualification, and validation of HVAC systems, cross-contamination and contamination, HVAC system and component design, protection of products, personnel, and the environment.

Comments are due to WHO by 12 July 2016.

Related News